Advertisement

Topics

Latest "FREDsense Technologies Corp" News Stories

13:31 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "FREDsense Technologies Corp" found in our extensive news archives from over 250 global news sources.

More Information about FREDsense Technologies Corp on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about FREDsense Technologies Corp for you to read. Along with our medical data and news we also list FREDsense Technologies Corp Clinical Trials, which are updated daily. BioPortfolio also has a large database of FREDsense Technologies Corp Companies for you to search.

Showing "FREDsense Technologies Corp" News Articles 1–25 of 4,600+

Relevant

RMMI Corp. Announces Supply Agreement With Namaste Technologies Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. CALGARY, Alberta, Sept. 26, 2018 (GLOBE NEWSWIRE) -- RMMI Corp. (“RMMI” or the “Company”) (CSE:RMMI) is pleased to announce that the Company’s wholly-owned subsidiary, Rocky Mountain Marijua...


Helix BioPharma Corp. Board Changes

RICHMOND HILL, Ontario, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced a change in the Company’s Board of Directors. The Board has accepted the resignation of Dr. Marek Orlowski as a director of the ...

CORRECTION from Source -- Emblem Corp.

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- In Emblem’s Q2 release issued 22-Aug-2018 by Emblem Corp. over GlobeNewswire, we are advised by the company that corrections were made to the Adjusted EBITDA in the Second Quarter Financial Summary table, and associated paragraph discussing the Adjusted EBITDA.  The complete corrected release follows: Emblem Corp. Reports Second Quarter 2018 Finan...


Emblem Corp. announces new board appointments

TORONTO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”) today announced the appointment of Connie A. Stefankiewicz and Loreto Grimaldi to its Board of Directors (the “Board”) following Emblem’s annual and special shareholders’ meeting. Harvey Shapiro, current chair, and Maxim Zavet have stepped down from the Board, and the Bo...

RMMI Corp. Completes Initial Public Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. CALGARY, Alberta, Sept. 24, 2018 (GLOBE NEWSWIRE) -- RMMI Corp. (“RMMI” or the “Company”) is pleased to announce today that it has successfully completed its initial public offering (the “Of...

RMMI Corp. to Commence Trading on the Canadian Securities Exchange

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. CALGARY, Alberta, Sept. 24, 2018 (GLOBE NEWSWIRE) -- RMMI Corp. (“RMMI” or the “Company”) is pleased to announce that its common shares will commence trading at the market open on Tuesday, Sep...

International Cannabis Corp. Building Global Network -- CFN Media

SEATTLE, Nov. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering International Cannabis Corp. (CSE: WRLD, OTC: KNHBF), also known as ICC, a vertically-integrated cannabis company specializing in the acquisition and ope...

Helix BioPharma Corp. Extends Period to Exercise Warrants

RICHMOND HILL, Ontario, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to extend the exercise period of a total of 4,546,000 outs...

Helix Biopharma Corp. Closes First Tranche of Private Placement

RICHMOND HILL, Ontario, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a first tranche of a private placement financing for gross proceeds of CAD871,200. The Company expects to complete a sec...

Helix BioPharma Corp. Closes Second Tranche of Private Placement

RICHMOND HILL, Ontario, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a second tranche of a private placement financing for gross proceeds of CAD342,000. The Company expects to complete a th...

Helix BioPharma Corp. Closes Third Tranche of Private Placement

RICHMOND HILL, Ontario, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a third tranche of a private placement financing for gross proceeds of CAD700,800. Helix closed the first and second tra...

Helix BioPharma Corp. Extends Annual Meeting Date

RICHMOND HILL, Ontario, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received consent from the Toronto Stock Exchange to extend the date of its annual general meeting of shareholders to a date not later than Apri...

Emblem Corp. Reports Second Quarter 2018 Financial Results

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”), a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), today reported financial and operating results for the three and six months ended June 30, 2018.  “I’m pleased to report a robust second quarter with subs...

Emblem Corp. Advances Funding for Natura Naturals Production

TORONTO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) (“Emblem” or the “Company”) has established a working capital advance (the “Advance”) for Natura Naturals Holdings Inc. (“Natura”) to support the completion of phase 1 construction while the two companies complete due diligence and negotiation of a definitive agreement in connection with the previou...

Scythian Biosciences Corp. Announces Andy DeFrancesco as a New Director

TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) announced today that it has appointed Andrew DeFrancesco to the Board of Directors effective September 4, 2018. Mr. DeFrancesco has over 26 years of capital markets experience, from senior positions at some of Canada’s most establish...

MediPharm Labs Corp. Announces Grant of Stock Options

TORONTO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (the “Company” or “MediPharm Labs”) is pleased to announce that the board of directors of the Company has approved the granting of options (the “Options”) to purchase up to 3,000,000 common shares in the capital of the Company to certain directors, officers, employees and consultants of MediPharm Labs pursu...

Emblem Corp. Reports Strong Third Quarter 2018 Financial Results

Revenues increase 281% over the quarter ended September 30, 2017 and 50% over Q2 2018 TORONTO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”), a licensed producer of cannabis under the Cannabis Act through its wholly owned subsidiary Emblem Cannabis Corporation, is pleased to report financial and operating results for the thr...

Golden Leaf Holdings Ltd. Not Pursuing Terra Tech Corp. Transaction

TORONTO, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF) (“Golden Leaf”), a cannabis company with cultivation, production and retail operations built around recognized brands announced today that it has decided not to pursue a potential transaction with Terra Tech Corp. (OTCQX: TRTC) (“Terra Tech”), a vertically integrated cannabis-focused agricultu...

International Cannabis Corp. Bolstering European Supply Chain -- CFN Media

SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering International Cannabis Corporation and its advanced European strategy. Europe’s population is twice the size of the US & Canada combined, but it's c...

Helix BioPharma Corp. Announces Fiscal 2018 Year-End Results

RICHMOND HILL, Ontario, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2018. FINANCIAL REVIEW The Company recorded a net loss and total comprehensive loss of $8,625,000 and $10,059,000 (...

Helix BioPharma Corp. Announces Fiscal First Quarter 2019 Results

RICHMOND HILL, Ontario, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2019 ending October 31, 2018. FINANCIAL REVIEW The Company recorded a net loss and total comprehensiv...

Helix BioPharma Corp. Closes Final Tranche of Private Placement

RICHMOND HILL, Ontario, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a final tranche of a private placement financing for gross proceeds of CAD348,000. The terms of the placement are ...

Helix BioPharma Corp. Provides Clinical Development and Strategic Corporate Update

RICHMOND HILL, Ontario, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer today provides an update on the Company’s strategic plans. Pre-clinical Development The Company extended its collaboration with the Moffitt Cance...

Zomedica Pharmaceuticals Corp. Announces Second Quarter 2018 Financial Results

ANN ARBOR, Mich., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the second quarter ended June 30, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting princip...

Terra Tech Corp Reports Financial Results for the Second Quarter of 2018

IRVINE, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Terra Tech Corp. (OTCQX: TRTC) (“Terra Tech” or the “Company”), a vertically integrated cannabis-focused agriculture company, today announced its second quarter financial results for the period ended June 30, 2018. “During the second quarter of fiscal 2018 we focused on both growing topline revenues, which reached $8.7 million for th...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks